- Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib
-
March-Rodriguez A, Bellosillo B, Ãlvarez-Larrán A, Besses C, Pujol RM, Toll A
- KMID: 2439067
- Ann Dermatol.
- 2019 Apr;31(2):204-208.
- doi: 10.5021/ad.2019.31.2.204
Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea. We report a 72... -
- CITED
-
- Close
- SHARE
-
- Close
